Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) Sees Significant Drop in Short Interest

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY - Get Free Report) saw a significant decrease in short interest in the month of May. As of May 31st, there was short interest totalling 9,100 shares, a decrease of 86.1% from the May 15th total of 65,600 shares. Approximately 0.0% of the company's shares are short sold. Based on an average daily trading volume, of 151,300 shares, the days-to-cover ratio is presently 0.1 days.

Chugai Pharmaceutical Price Performance

OTCMKTS CHGCY traded down $0.38 during mid-day trading on Friday, reaching $25.91. 63,564 shares of the stock were exchanged, compared to its average volume of 186,788. The stock has a market cap of $85.27 billion, a P/E ratio of 33.65 and a beta of 0.68. The stock has a 50 day simple moving average of $26.61 and a 200-day simple moving average of $23.99. Chugai Pharmaceutical has a one year low of $15.26 and a one year high of $31.26.

Chugai Pharmaceutical (OTCMKTS:CHGCY - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The company reported $0.19 earnings per share for the quarter. Chugai Pharmaceutical had a return on equity of 21.53% and a net margin of 33.07%. The firm had revenue of $1.89 billion during the quarter. Sell-side analysts anticipate that Chugai Pharmaceutical will post 0.74 EPS for the current fiscal year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.